

A Study to Compare the Effect of Two Blinded Doses of Casodex (ICI 176,334 100 mg and 150 mg daily) and Castration in the Treatment of Advanced Carcinoma of the Prostate

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 21/01/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

A Study to Compare the Effect of Two Blinded Doses of Casodex (ICI 176,334 100 mg and 150 mg daily) and Castration in the Treatment of Advanced Carcinoma of the Prostate

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Prostate

Interventions

STAGE I PATIENTS: Patients are randomised to either:

1. Casodex 100 mg
2. Casodex 150 mg
3. Castration

STAGE II PATIENTS: Patients are randomised to either:

1. Casodex 150 mg
2. Castration

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Casodex

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1990

Completion date

30/06/1993

Eligibility**Key inclusion criteria**

1. Locally advanced stage T3 or T4 carcinoma of the prostate with prostate-specific antigen times five the upper limit of normal or metastatic disease
2. Gleason grade 2-10
3. Evaluable disease
4. Fit to receive treatment

Participant type(s)

Patient

Age group

Not Specified

Sex

Male

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1990

Date of final enrolment

30/06/1993

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

Sponsor information**Organisation**

AstraZeneca Clinical Research Group (UK)

Sponsor details

10 Logie Mill

Beaverbank Office Park

Lovie Green Road

Edinburgh

United Kingdom

EH7 4HG

Sponsor type

Industry

Website

<http://www.astrazeneca.co.uk>

ROR

<https://ror.org/04r9x1a08>

Funder(s)**Funder type**

Industry

Funder Name

AstraZeneca Pharmaceuticals (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/1998	21/01/2019	Yes	No